ArticleThe oncologist2025

Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients.

Alberto Farolfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.